CD19/CD22 CAR T-cells

Therapeutically relevant doses of CD19/CD22 CAR-T cells can be successfully manufactured from whole blood. On average, 80 mL of whole blood yields enough CAR-T cells to create a single dose for a pediatric patient (50 kg) at a dosage of 1 × 106 CAR-T cells/kg. For larger patients, scaling up is straightforward by collecting a larger blood volume. This method also demonstrates a cost-effective approach to T cell activation and expansion which, alongside a more straightforward collection of whole blood, makes it more widely accessible especially for middle- and low-income countries. By reducing costs and labor, this strategy has the potential to significantly expand global access to CAR-T cell therapy.

P1/2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=30 --> 0 | Trial completion date: Aug 2023 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2023 --> Nov 2022

P1, N=140, Recruiting, National Cancer Institute (NCI) | N=87 --> 140

P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Aug 2022 --> Aug 2023

P1, N=87, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2032 --> Dec 2040 | Trial primary completion date: Dec 2022 --> Dec 2025

P1, N=87, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2021 --> Dec 2022